Close Menu

Oxford Nanopore

Oxford Nanopore Technologies was founded in 2005 to develop an electronic, single molecule sensing system based on nanopore science. The company now has more than 250 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialization. Oxford Nanopore's instruments MinIon, PromethIon, and GridIon are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule.

Oxford Nanopore Facts

  • CEO: Gordon Sanghera
  • Website: www.nanoporetech.com
  • Ticker symbol: Privately held
  • Headquarters: Oxford, UK
  • Number of employees: 250+

Numbers Needed

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

The UK is implementing COVID-19 testing with a 90-minute turnaround time.

Both tests can detect SARS-CoV-2 in 90 minutes and will detect viruses like influenza and respiratory syncytial virus that tend to occur in the winter.

The new pore, a complex between E. coli CsgG and part of CsgF, called certain homopolymers more accurately than an engineered version of CsgG.

The company is also working on a diagnostic COVID-19 test, called LamPore, that will run on its MinIon and GridIon nanopore sequencing platforms

Combining Ubiquitome's handheld PCR device and Oxford Nanopore's sequencer may enable a single person to screen 500 samples and obtain 24 whole genome sequences per day.

The researchers said a functional investigation of the virus' unknown transcripts and RNA modifications will elucidate its life cycle and pathogenicity.

GenomeWeb asked a number of prominent researchers in the field via email about their top picks for notable developments or achievements in genomics during the 2010s.

Pages

According to Science, the US National Academy of Sciences is poised to eject two members accused of sexual harassment.

A UK study on mixing SARS-CoV-2 vaccines is expanding to include vaccines developed by additional companies, according to the Guardian.

In Nucleic Acids Research this week: machine learning approach to detect DNA-bound proteins, CRISPR-based method for activating specific gene targets, and more.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.